Graybug Vision (GRAY) Competitors $1.99 -0.08 (-3.86%) As of 03/28/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsTrendsBuy This Stock GRAY vs. GOVX, APRE, CSCI, SNSE, MBRX, BLRX, TLPH, QNTM, TRAW, and APLMShould you be buying Graybug Vision stock or one of its competitors? The main competitors of Graybug Vision include GeoVax Labs (GOVX), Aprea Therapeutics (APRE), COSCIENS Biopharma (CSCI), Sensei Biotherapeutics (SNSE), Moleculin Biotech (MBRX), BioLineRx (BLRX), Talphera (TLPH), Quantum Biopharma (QNTM), Traws Pharma (TRAW), and Apollomics (APLM). These companies are all part of the "pharmaceutical preparations" industry. Graybug Vision vs. GeoVax Labs Aprea Therapeutics COSCIENS Biopharma Sensei Biotherapeutics Moleculin Biotech BioLineRx Talphera Quantum Biopharma Traws Pharma Apollomics GeoVax Labs (NASDAQ:GOVX) and Graybug Vision (NASDAQ:GRAY) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, community ranking, institutional ownership, media sentiment, dividends, valuation and profitability. Which has more volatility and risk, GOVX or GRAY? GeoVax Labs has a beta of 3.06, indicating that its share price is 206% more volatile than the S&P 500. Comparatively, Graybug Vision has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500. Is GOVX or GRAY more profitable? Graybug Vision's return on equity of -77.61% beat GeoVax Labs' return on equity.Company Net Margins Return on Equity Return on Assets GeoVax LabsN/A -809.87% -349.34% Graybug Vision N/A -77.61%-71.34% Which has preferable earnings & valuation, GOVX or GRAY? GeoVax Labs has higher revenue and earnings than Graybug Vision. GeoVax Labs is trading at a lower price-to-earnings ratio than Graybug Vision, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGeoVax Labs$3.09M3.27-$25.97M-$5.67-0.19Graybug VisionN/AN/A-$35.60M-$24.23-0.08 Does the MarketBeat Community favor GOVX or GRAY? GeoVax Labs received 10 more outperform votes than Graybug Vision when rated by MarketBeat users. Likewise, 96.30% of users gave GeoVax Labs an outperform vote while only 50.00% of users gave Graybug Vision an outperform vote. CompanyUnderperformOutperformGeoVax LabsOutperform Votes2696.30% Underperform Votes13.70%Graybug VisionOutperform Votes1650.00% Underperform Votes1650.00% Do analysts rate GOVX or GRAY? GeoVax Labs presently has a consensus target price of $14.20, suggesting a potential upside of 1,225.74%. Given GeoVax Labs' stronger consensus rating and higher probable upside, equities analysts plainly believe GeoVax Labs is more favorable than Graybug Vision.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GeoVax Labs 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29Graybug Vision 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals and insiders believe in GOVX or GRAY? 6.1% of GeoVax Labs shares are owned by institutional investors. Comparatively, 49.9% of Graybug Vision shares are owned by institutional investors. 5.7% of GeoVax Labs shares are owned by company insiders. Comparatively, 7.9% of Graybug Vision shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the media refer more to GOVX or GRAY? In the previous week, GeoVax Labs had 13 more articles in the media than Graybug Vision. MarketBeat recorded 13 mentions for GeoVax Labs and 0 mentions for Graybug Vision. GeoVax Labs' average media sentiment score of 0.58 beat Graybug Vision's score of 0.00 indicating that GeoVax Labs is being referred to more favorably in the media. Company Overall Sentiment GeoVax Labs Positive Graybug Vision Neutral SummaryGeoVax Labs beats Graybug Vision on 13 of the 17 factors compared between the two stocks. Remove Ads Get Graybug Vision News Delivered to You Automatically Sign up to receive the latest news and ratings for GRAY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GRAY vs. The Competition Export to ExcelMetricGraybug VisionPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.13M$6.87B$5.61B$7.68BDividend YieldN/A2.79%5.33%4.02%P/E Ratio-1.157.3523.5018.55Price / SalesN/A208.36376.0088.66Price / CashN/A65.6738.1734.64Price / Book1.196.256.814.11Net Income-$35.60M$142.34M$3.20B$247.18M7 Day Performance-1.00%-8.43%-5.42%-4.05%1 Month Performance-12.72%-9.99%-0.12%-6.41%1 Year Performance-52.16%-12.60%7.61%-2.08% Graybug Vision Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GRAYGraybug VisionN/A$1.99-3.9%N/A-52.2%$3.13MN/A-1.1527High Trading VolumeGOVXGeoVax Labs3.0203 of 5 stars$1.40+6.9%$14.20+914.3%-44.5%$12.36M$3.09M0.0010Earnings ReportAnalyst ForecastShort Interest ↓Analyst RevisionAPREAprea Therapeutics2.8654 of 5 stars$2.26-5.4%$15.50+585.8%-68.8%$12.28M$580,000.00-0.807Earnings ReportShort Interest ↑Analyst RevisionGap UpCSCICOSCIENS BiopharmaN/A$3.22+0.6%N/AN/A$12.16M$7.60M-0.2720High Trading VolumeSNSESensei Biotherapeutics4.5411 of 5 stars$0.46-5.2%$4.33+832.7%-51.6%$11.69MN/A-0.3940Earnings ReportUpcoming EarningsAnalyst ForecastShort Interest ↓Gap DownMBRXMoleculin Biotech2.8814 of 5 stars$1.06-2.8%$18.67+1,661.0%-82.4%$11.51MN/A0.0020Short Interest ↓BLRXBioLineRx2.8056 of 5 stars$3.42-4.5%$360.00+10,426.3%-93.2%$11.39M$21.99M-0.3940News CoverageGap UpTLPHTalphera2.1041 of 5 stars$0.64+0.7%$4.33+578.0%-43.1%$10.88M$281,000.00-0.9319Short Interest ↑News CoverageQNTMQuantum BiopharmaN/A$5.55-1.9%N/AN/A$10.65MN/A-0.36N/AEarnings ReportNews CoverageGap UpTRAWTraws Pharma1.1708 of 5 stars$2.84flatN/AN/A$10.37M$226,000.00-0.0217Upcoming EarningsGap UpAPLMApollomics2.568 of 5 stars$9.50-4.0%$200.00+2,005.3%-89.8%$10.33M$1.22M0.0045News CoverageGap Up Remove Ads Related Companies and Tools Related Companies GOVX Competitors APRE Competitors CSCI Competitors SNSE Competitors MBRX Competitors BLRX Competitors TLPH Competitors QNTM Competitors TRAW Competitors APLM Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GRAY) was last updated on 3/31/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Great Society Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Graybug Vision, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Graybug Vision With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
